Valirx (VAL)

 

Latest News

ValiRx notes positive VAL201 clinical trial

ValiRx announces positive results in its VAL201 personalised Phase l/II prostate cancer study with accumulation of safety a...

CLINICAL TRIAL UPDATE - Positive VAL201 Results

RNS Number: 8311T ValiRx PLC 11 January 2017 y Va li R x P lc ("ValiRx" or "the Company") CLINICAL TRIAL UPDATE 'Positive VAL201 Results' London, UK ., 11 January 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces positive results in its VAL201 personalised Phase l/II prostate cancer study with accumulation of safety and to...

ValiRx notes Yorkville CLN conversion

ValiRx said YA Global Master SPV Ltd (Yorkville) has elected to convert a further portion of tranche 1 of the Convertible...

Yorkville CLN Conversion

RNS Number: 0006T ValiRx PLC 30 December 2016 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Yorkville CLN Conversion London, UK ., 29 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards comm...

All News

DateHeadlineSource
11-01-17ValiRx notes positive VAL201 clinical trialStockMarketWire
11-01-17CLINICAL TRIAL UPDATE - Positive VAL201 ResultsRNS
30-12-16ValiRx notes Yorkville CLN conversionStockMarketWire
30-12-16Yorkville CLN ConversionRNS
08-12-16ValiRx says European patent granted for VAL201StockMarketWire
08-12-16European Patent Granted for Lead Compound VAL201RNS
02-12-16ValiRx loan draw downStockMarketWire
02-12-16Convertible Loan FacilityRNS
01-12-16ValiRx notes ValiSeek clinical development updateStockMarketWire
01-12-16ValiSeek Clinical Development UpdateRNS
01-12-16ValiRx Plc - ValiSeek Clinical Development UpdateBRR Media
29-11-16Quarterly Update on Clinical DevelopmentsRNS
03-11-16ValiSeek Clinical Development UpdateRNS
02-11-16ValiRx plc - Valiseek clinical development update BRR Media
28-10-16Corporate Video re Clinical Status Q4, 2016RNS
28-10-16ValiRX - Clinical Status Q4 2016BRR Media
25-10-16ValiRx issues patent updateStockMarketWire
25-10-16Patent UpdateRNS
13-10-16Holding(s) in CompanyRNS
13-10-16Holding(s) in CompanyRNS
13-10-16Update on Recent PresentationsRNS
12-10-16Result of General MeetingRNS
05-10-16CLN ConversionRNS
28-09-16Notice of GMRNS
27-09-16Half-year ReportRNS
27-09-16ValiRx - Half-year ReportBRR Media
26-09-16ValiRx selected for The Parliamentary Review 2016RNS
13-09-16Quarterly Update on Clinical DevelopmentsRNS
13-09-16ValiRx - Quarterly update on clinical developmentsBRR Media
09-09-16Valirx Plc to present at the SHARES Investor Evening in Edinburgh on 5th October 2016StockMarketWire
02-09-16Placing, issue of warrants & Convertible LoanRNS
19-08-16Valirx Plc to present at the Shares LIVE Show in London on 10th September 2016StockMarketWire
11-08-16ValiRx gives ValiSeek clinical development updateStockMarketWire
11-08-16ValiSeek Clinical Development UpdateRNS
11-08-16ValiRx Plc - ValiSeek clinical development updateBRR Media
04-08-16Issue of EquityRNS
29-07-16ValiRx - New Zealand Patent Grant AllowanceBRR Media
28-07-16ValiRx notes notification of NZ Patent Grant AllowanceStockMarketWire
28-07-16Notification of New Zealand Patent Grant AllowanceRNS
26-07-16ValiRx issues equity, discontinues Bracknor facilityStockMarketWire

RSS feeds

  • Editorial news feed for LSE:VAL Editorial
  • Regulatory news feed for LSE:VAL Regulatory